Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab dose comparison with cisplatin and capecitabine in HER2-positive metastatic gastric or gastro-esophageal junction adenocarcinoma
2011-001526-19Phase 3Terminated
- Sponsor
- Roche
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Roche. Primary endpoint: Overall survival in all randomized patients. Started Sep 2011; status: terminated.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2011-001526-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001526-19.